--- title: "Ascendis Pharma (ASND) news: buyback" url: "https://aibio.space/companies/ascendis-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ASND buyback news. Ascendis Pharma news for investors: Ascendis Pharma is a Danish company that uses its TransCon technology to make longer-acting versions…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Ascendis is profitable, but one drug carries most of the revenue Ascendis is profitable, with three marketed TransCon drugs and a clear European decision due this quarter. Its risks are reliance on YORVIPATH for most revenue, a royalty to BioMarin and the end of the Novo partnership in obesity. Read the full desk view aibio.space Investor Rank · Opinion **9** /10 Most positive view Profitable with three marketed TransCon drugs and an EU YUVIWEL decision due this quarter, though YORVIPATH supplies about 80% of product revenue. - **Technology**: 2/2 - **Odds**: 2/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 2/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Proven platform.** TransCon underpins three marketed products, YORVIPATH, SKYTROFA and YUVIWEL, and a combination of two of them is heading to phase 3. - **Odds**: **Favorable near term.** The EU decision on YUVIWEL is due in Q4 2026 after a positive CHMP opinion, and rare disease filings historically win approval 93.6% of the time. - **Balance sheet**: **Solid.** Cash was €812 million at June 30 with positive operating cash flow, and the convertible notes were converted into equity. - **Main risk**: **Concentration.** YORVIPATH is about 80% of product revenue, and the BioMarin royalty and Novo rights reversion add cost and strategic questions. - **Watch next**: **European Commission decision on YUVIWEL.** Ascendis expects it in Q4 2026, with a German launch in Q1 2027 if approved. ## Top news on Ascendis 1. 2026-09-14 Financings [Ascendis takes back obesity rights from Novo Nordisk and authorizes $400 million buyback](https://aibio.space/news/ascendis-takes-back-obesity-rights-novo-nordisk-authorizes-400-million/) All TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations. ## Dates **Q4 2026** European Commission decision on YUVIWEL (TransCon CNP) in achondroplasia [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526423938/d167361d6k.htm) **Q4 2026** Start of phase 3 enrollment for TransCon CNP plus TransCon hGH in achondroplasia [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) **Around end of 2026** COACH week 104 data [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526210386/d121855dex991.htm) **H2 2026** Start of phase 3 trial of TransCon CNP in hypochondroplasia [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) **Q1 2027** First EU launch of YUVIWEL in Germany, if authorized [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526423938/d167361d6k.htm) ## The money Cash and cash equivalents of €812 million at June 30, 2026 (€616 million at Dec 31, 2025). First-half operating cash flow €274 million; $575 million of convertible notes converted to equity in May; $400 million share repurchase authorized Sept 14, 2026. No runway guidance; the company is profitable. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) Q2 2026 product revenue €315 million (+105%): YORVIPATH €252 million, SKYTROFA €55 million, YUVIWEL €8 million. Total revenue €339 million. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) ## Risks on the record - Revenue is concentrated: YORVIPATH was €252 million of €315 million Q2 product revenue. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) - BioMarin settlement is a binding term sheet; Ascendis would pay royalties of 20% (US) and 18% (EU, South Korea, Brazil) on navepegritide-related net sales through May 20, 2030, pending a definitive agreement. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526376733/d139239d6k.htm) - Novo Nordisk rights in metabolic and cardiovascular disease reverted on Sept 14, 2026, leaving obesity programs without a partner. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526390877/d183438d6k.htm) ## Questions investors ask ### What is aibio.space's Investor Rank for Ascendis Pharma? 9 out of 10, our most positive view. Profitable with three marketed TransCon drugs and an EU YUVIWEL decision due this quarter, though YORVIPATH supplies about 80% of product revenue. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### When will the European Commission decide on Ascendis's YUVIWEL (navepegritide)? The CHMP gave a positive opinion on October 15, 2026. Ascendis expects the European Commission decision in the fourth quarter of 2026, and a first EU launch in Germany in the first quarter of 2027 if it is authorized. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526423938/d167361d6k.htm) ### How much revenue does Ascendis Pharma have? Second-quarter 2026 product revenue was €315 million, up 105% from a year earlier. YORVIPATH contributed €252 million, SKYTROFA €55 million and YUVIWEL €8 million. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) ### What happened between Ascendis and Novo Nordisk? On September 14, 2026, Ascendis said it would regain all rights to TransCon products in metabolic and cardiovascular disease, including once-monthly TransCon semaglutide. Neither company has continuing financial obligations to the other. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526390877/d183438d6k.htm) ### What did Ascendis agree with BioMarin? A binding term sheet signed on August 31, 2026 would settle all litigation. Ascendis gets a non-exclusive worldwide license and pays royalties of 20% of net sales in the US and 18% in the EU, South Korea and Brazil, through May 20, 2030. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526376733/d139239d6k.htm) ### Is Ascendis Pharma profitable? Ascendis reported a second-quarter 2026 net profit of €207 million, which included a €158 million priority review voucher sale. On a non-IFRS basis, net profit was €61 million, or €0.90 per diluted share. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) ### What is the latest Ascendis Pharma (ASND) stock news? Our latest story on Ascendis Pharma, dated Sep 14, 2026: "Ascendis takes back obesity rights from Novo Nordisk and authorizes $400 million buyback". All TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations. [Source](https://aibio.space/news/ascendis-takes-back-obesity-rights-novo-nordisk-authorizes-400-million/) ### What is Ascendis Pharma's latest stock offering or financing news? Our latest financing story, dated Sep 14, 2026: "Ascendis takes back obesity rights from Novo Nordisk and authorizes $400 million buyback". All TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations. [Source](https://aibio.space/news/ascendis-takes-back-obesity-rights-novo-nordisk-authorizes-400-million/) ### Is Ascendis Pharma a smaller reporting company? SEC records list Ascendis Pharma A/S's filer category as: Large accelerated filer. Source ### Where is Ascendis Pharma headquartered? SEC records list its business address as TUBORG BOULEVARD 12, HELLERUP. Source ### When does Ascendis Pharma's fiscal year end? Ascendis Pharma A/S's fiscal year ends on December 31, per SEC records. Source ### What did Ascendis Pharma last file with the SEC? Its most recent filing in our record is a 6-K filed 2026-10-16. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526423938/d167361d6k.htm) ### What industry is Ascendis Pharma in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ### How can I follow Ascendis Pharma (ASND) news? Press Follow on this page to add Ascendis Pharma to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Ascendis Pharma so far, in Financings. Source ## Legal and investor matters Checked against Ascendis Pharma filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. The Legal Proceedings section of the 20-F filed in February 2026 gives BioMarin's patent proceedings as its example of claims it may face. It does not mention a securities class action or derivative suit. This covers that filing only. [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm) 1. 2026-08-31 Litigation Ascendis and BioMarin agree binding term sheet to settle all litigation Ascendis said in a 6-K that on August 31, 2026 it announced a binding term sheet with BioMarin for a global settlement and license covering YUVIWEL and navepegritide-related products. BioMarin grants a non-exclusive worldwide royalty-bearing license and agrees to dismiss all proceedings, and Ascendis agrees to dismiss its proceedings against BioMarin. Ascendis would pay royalties of 20% on U.S. net sales and 18% in the European Union, South Korea and Brazil through May 20, 2030. Status: settled [Ascendis Pharma 6-K filed 2026-08-31](https://www.sec.gov/Archives/edgar/data/1612042/000119312526376733/d139239d6k.htm) 2. 2026-08-13 Litigation BioMarin ITC patent complaint against Ascendis reached trial in April 2026 In its interim report furnished August 13, 2026, Ascendis said BioMarin filed a complaint with the U.S. International Trade Commission alleging infringement of U.S. Reissue Patent No. 48,267, and that trial took place in April 2026. Ascendis started a related action in the U.S. District Court for the Northern District of California, which is stayed pending the ITC proceedings. Ascendis says it believes BioMarin's claims lack merit. The August 31 term sheet later addressed these disputes. U.S. International Trade Commission · Status: pending [Ascendis Pharma 6-K filed 2026-08-13](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm) 3. 2025-12-29 Litigation UPC dismisses BioMarin patent case against Ascendis after EPO revocation Ascendis reported in its 20-F that the EPO Technical Boards of Appeal revoked BioMarin's EP3175863 patent in its entirety on October 16, 2025. As a consequence, the Unified Patent Court dismissed BioMarin's infringement case in Munich on December 29, 2025, and BioMarin agreed to reimburse certain legal expenses. Ascendis also instituted proceedings in the Danish Maritime and Commercial High Court over divisional applications of the revoked patent. Unified Patent Court, Munich · Status: dismissed [Ascendis Pharma 20-F filed 2026-02-11](https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | YORVIPATH (palopegteriparatide, TransCon PTH) | Hypoparathyroidism | Marketed; label expansion trials PaTHway60 and PaTHway Adolescent [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) | | SKYTROFA (lonapegsomatropin, TransCon hGH) | Growth hormone deficiency; other growth disorders | Marketed; phase 3 HighLiGHts basket trial ongoing [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) | | YUVIWEL (navepegritide, TransCon CNP) | Achondroplasia in children aged 2 and older | FDA accelerated approval (Feb 2026); CHMP positive opinion Oct 15, 2026 [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526423938/d167361d6k.htm) | | TransCon CNP plus TransCon hGH | Achondroplasia | Phase 2 COACH, 78-week data; phase 3 enrollment to start Q4 2026 [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526337270/d169607d6k.htm) | | TransCon CNP infant trial (reACHin) | Achondroplasia in infants 0 to under 2 years | Target enrollment complete; filings planned [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) | | TransCon CNP monotherapy | Hypochondroplasia | Phase 3 expected to begin enrolling in H2 2026 [Source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) | Opinion · Devil's advocate ## Fact-check-o-meter Some gaps Ascendis messaging mostly matches its filings, but the combo data and the profit headline need context Ascendis's releases are largely in line with its interim report and 20-F, and the company is profitable with no going-concern language. The gaps are in emphasis: a one-time voucher sale drives the headline operating margin, recent releases drop the word 'accelerated' from YUVIWEL's U.S. approval, and the 'tripling of efficacy' claim for the combination rests on a 21-child open-label trial with no concurrent control. On Aug. 31, 2026 Ascendis filed a 6-K saying it had entered into a binding term sheet to settle all litigation with BioMarin, including the U.S. ITC case tried in April 2026, with a definitive agreement still to come. 1. Press release vs filing · weight low Q2 operating margin includes a one-time voucher sale **The company said:** "Operating profit for the second quarter of 2026 totaled €220 million, reflecting a margin of 65%. On a non-IFRS basis, operating profit was €92 million*, reflecting a margin of 27%*." [source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) **The record says:** The interim report says the PRV sale closed in the second quarter and "The income from sale of the PRV, net of transaction costs was € 158.1 million and is presented as other operating income". It is also "included within cash flows from operating activities in the statements of cash flows". [source](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm) **Our view:** The release does show the non-IFRS figure next to the IFRS one, so nothing is hidden. Still, the 65% margin and the first-half operating cash flow both carry a voucher sale that cannot repeat, and the 27% non-IFRS margin is the better guide to the run rate. 2. Press release vs filing · weight medium Recent releases drop 'accelerated' from YUVIWEL's U.S. approval **The company said:** "Making YUVIWEL available in select International Markets countries through early access programs using U.S. FDA approval." [source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) **The record says:** The February approval report states the drug was approved "under the FDA's Accelerated Approval Program" and that "Continued approval for this indication, which was based on an improvement in annualized growth velocity, may be contingent upon verification and description of clinical benefit in confirmatory trial(s)." The interim report repeats: "In February 2026, we received accelerated approval of YUVIWEL". [source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526084021/d116890d6k.htm) **Our view:** The August results release and the August 6 program update describe YUVIWEL's FDA status without the word accelerated. The approval rests on growth velocity, a surrogate, so U.S. revenue depends on confirmatory data the later releases do not discuss. 3. Science · weight medium 'Tripling of efficacy' comes from an open-label, single-arm phase 2 **The company said:** "sustained increases in ACH-specific height Z-score, indicating a tripling of efficacy compared to TransCon CNP monotherapy." [source](https://www.sec.gov/Archives/edgar/data/1612042/000119312526337270/d169607d6k.htm) **The record says:** The release itself calls COACH "an ongoing prospective Phase 2 open-label trial" with cohorts of "N=12" and "N=9". The ClinicalTrials.gov record lists a single-group design with no masking, an actual enrollment of 22, and a primary endpoint of growth velocity at week 52 measured as "cm per year, compared to navepegritide alone". [source](https://clinicaltrials.gov/api/v2/studies/NCT06433557) **Our view:** With no concurrent control arm, the comparison to monotherapy is against other trials, and the treatment-experienced cohort is small. The registry's enrollment of 22 also differs from the 21 children in the release. The planned phase 3 is where the 'tripling' claim gets a real test. 4. Legal and disclosure record · weight medium BioMarin patent litigation, including the U.S. ITC case, is covered by an Aug. 31 binding term sheet to settle **The record says:** The interim report says BioMarin filed "a complaint filed with the U.S. International Trade Commission ("ITC") related to alleged infringement of U.S. Reissue Patent No. 48,267. Trial in the ITC took place this April 2026." Ascendis's own suit in the U.S. Northern District of California "has been stayed in view of the pending ITC proceedings." The European '863 patent was revoked on October 16, 2025 and the UPC case dismissed. A 6-K filed on Aug. 31, 2026, after the interim report, says Ascendis "entered into a binding term sheet for a global settlement and license agreement with BioMarin" and that the term sheet "provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies". Ascendis would pay royalties of 20% in the United States and 18% in the European Union, South Korea and Brazil on net sales of navepegritide-related products through May 20, 2030, and each side would dismiss its proceedings against the other. The 6-K refers to an anticipated definitive agreement. A 6-K filed on Aug. 31, 2026, after the interim report, says Ascendis "entered into a binding term sheet for a global settlement and license agreement with BioMarin" and that the term sheet "provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies". Ascendis would pay royalties of 20% in the United States and 18% in the European Union, South Korea and Brazil on net sales of navepegritide-related products through May 20, 2030, and each side would dismiss its proceedings against the other. The 6-K refers to an anticipated definitive agreement. A 6-K filed on Aug. 31, 2026, after the interim report, says Ascendis "entered into a binding term sheet for a global settlement and license agreement with BioMarin" and that the term sheet "provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies". Ascendis would pay royalties of 20% in the United States and 18% in the European Union, South Korea and Brazil on net sales of navepegritide-related products through May 20, 2030, and each side would dismiss its proceedings against the other. The 6-K refers to an anticipated definitive agreement. No securities litigation or enforcement action is disclosed. [source](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm) **Our view:** The August results release and the October CHMP release mention litigation only in generic forward-looking language and do not mention the term sheet. The interim report says Ascendis believes BioMarin's claims lack merit, while the later 6-K describes a settlement with royalty payments, so the definitive agreement and its final terms are the facts to follow. Documents we compared - [Q2 2026 results press release (6-K exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526348046/d31437dex991.htm) 2026-08-13 - [Interim report for the period ended June 30, 2026 (6-K)](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000016/asnd-20260630.htm) 2026-08-13 - [Achondroplasia program update incl. Week 78 COACH data (6-K)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526337270/d169607d6k.htm) 2026-08-06 - [CHMP positive opinion for TransCon CNP (6-K)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526423938/d167361d6k.htm) 2026-10-16 - [YUVIWEL FDA accelerated approval (6-K)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526084021/d116890d6k.htm) 2026-03-02 - [Annual report on Form 20-F for 2025](https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm) 2026-02-11 - [ClinicalTrials.gov NCT06433557 (COACH)](https://clinicaltrials.gov/api/v2/studies/NCT06433557) 2026-10-23 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ASND on TradingView](https://www.tradingview.com/symbols/NASDAQ-ASND/). ## SEC filings and registration - **SEC name**: Ascendis Pharma A/S - **CIK**: 1612042 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ASND (Nasdaq) - **State or country of incorporation**: G7 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: TUBORG BOULEVARD 12, HELLERUP - **Phone**: 45 70 22 22 44 - **Shares outstanding**: 61,977,408 as of 2025-12-31 (20-F filed 2026-02-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526423938/d167361d6k.htm) filed 2026-10-16 - [6-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526421789/d743945d6k.htm) filed 2026-10-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526407293/d153773d6k.htm) filed 2026-09-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526390877/d183438d6k.htm) filed 2026-09-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526390874/d52763d6k.htm) filed 2026-09-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526386630/d152057d6k.htm) filed 2026-09-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526386434/d32116d6k.htm) filed 2026-09-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526376733/d139239d6k.htm) filed 2026-08-31 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001612042), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ascendis-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Ascendis Pharma (ASND) news: buyback", 2026-10-31, https://aibio.space/companies/ascendis-pharma/